AAREY DRUGS & PHARMACEUTICALS
|
|
BOM : 524412     NSE : AAREYDRUGS     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Jun 10,2025 |
Price(EOD): ₹ 54.89
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 155.89 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
AAREY DRUGS & PHARMACEUTICALS | 9.3% | 1.7% | 18.6% |
SUN PHARMACEUTICAL INDUSTRIES | 1.4% | 0.1% | 13.9% |
DIVIS LABORATORIES | 0.8% | 12.3% | 47.2% |
CIPLA | 2.6% | -0.1% | 0.6% |
TORRENT PHARMACEUTICALS | 2.7% | -0.6% | 14.4% |
DR REDDYS LABORATORIES | 7.8% | 12.9% | 13.3% |
MANKIND PHARMA | 1.3% | -4.8% | 9.3% |
ZYDUS LIFESCIENCES | 5.4% | 11% | -7.3% |
LUPIN | 3.3% | -1.7% | 22.3% |
FUNDAMENTAL ANALYSIS OF AAREY DRUGS & PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF AAREY DRUGS & PHARMACEUTICALS
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
38.7
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 4.02 Cr
[Latest Qtr - Mar2025 - Standalone Results ] 1.19
P/B Calculated based on Book Value of Rs 130.31 Cr
[Latest Year - Mar2024 - Standalone Results ] 0.33
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Mar2025 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
1925% 23% 29% |
SHARE PRICE MOMENTUM OF AAREY DRUGS & PHARMACEUTICALS
AAREY DRUGS & PHARMACEUTICALS vs SENSEX
DEBT OF AAREY DRUGS & PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.24 0.33 0.13 0.23 |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF AAREY DRUGS & PHARMACEUTICALS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2025 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF AAREY DRUGS & PHARMACEUTICALS
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-19.2% -320.39% 16.07% -34.54% |
-48.61% -237.25% -24.24% -78.15% |
QtrlyTrend |
-6 | |
Latest Qtr: Mar2025 | ||
Quarterly Result Analysis → |
AAREY DRUGS & PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about AAREY DRUGS & PHARMACEUTICALS
Is AAREY DRUGS & PHARMACEUTICALS good for long term investment?
As on Jun 10,2025, the Fundamentals of AAREY DRUGS & PHARMACEUTICALS look Poor and hence it may not be good for long term investment ! See Financial Performance of AAREY DRUGS & PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is AAREY DRUGS & PHARMACEUTICALS UnderValued or OverValued?
As on Jun 10,2025, AAREY DRUGS & PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of AAREY DRUGS & PHARMACEUTICALS ?
As on Jun 10,2025, the Intrinsic Value of AAREY DRUGS & PHARMACEUTICALS is Rs. 42.53 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 2.71
Fair Value [Median EV / Sales Model] : Rs. 44.57
Fair Value [Median Price / Sales Model] : Rs. 42.53
Estimated Median Fair Value of AAREY DRUGS & PHARMACEUTICALS : Rs. 42.53
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.